Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
about
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responsesThe evolution of poxvirus vaccinesSynthetic DNA vaccine strategies against persistent viral infectionsA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenDeletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-CImmunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletionsImproved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectorsA human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virusDendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Attenuation of vaccinia Tian Tan strain by removal of viral TC7L-TK2L and TA35R genes.Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensImproving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysVirological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman PrimatesRemoval of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in miceThe poxvirus C7L host range factor superfamily.Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens.Enhancing poxvirus vectors vaccine immunogenicity.High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.Involvement of the cellular phosphatase DUSP1 in vaccinia virus infection.Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-SpeciA Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.Modulating Vaccinia Virus Immunomodulators to Improve Immunological Memory.Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene ExpressionPotent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
P2860
Q21135240-9C10BEEB-931D-4B00-B547-076368E7C1DCQ26995905-073FCE26-5957-456D-9C5D-85922B22E07AQ27016078-41A7E30A-E4B2-487B-A666-FE74F66F9DF1Q27302081-126987F4-167A-4734-A1B8-E9A4E41DBE10Q27306437-F9FF9686-5B3C-4BC0-8192-D5B5912487ABQ27320923-177BD51B-D1A3-42AC-9A72-E414BE93195BQ28742751-5ACAF74D-6B94-43C9-8B0E-73EDA4B54FFBQ31037728-38483B30-9149-47DF-AF1D-0382D9E1179EQ33916776-9C6322D6-2949-43E5-A182-6C73E7CB04FDQ34171543-6E0A9D68-A9CE-4DCD-BDE3-1FF2B04B84B9Q34247289-65EE5599-C23E-4B22-9B5E-DE7AF66CDE9EQ34310410-F216AB64-8741-41D5-B316-3758CFD2B8DCQ34465228-5DD163FE-309F-4A58-8076-6B6E5CF8620EQ34796206-9C6E2B87-F123-4919-9771-44B943FC59EFQ34991112-57DD65D0-A356-42E8-8456-DAB1246C6997Q35076706-A46D6921-3237-49F2-962F-9BE140C121EFQ35212666-C89E5C24-8FE6-4BFE-B013-74BC54445F0AQ35914311-AC8357D8-0E0E-483D-9EC9-049DCED6BDA3Q35943846-6E426985-5C04-4A69-A143-EEABEB49ADC4Q36427971-1B7FE711-ACC4-49A9-A13E-EB828123C3E8Q36911682-1633A559-74A3-41D6-BC18-71A03569AF72Q36978452-C6FE9CAA-2066-40AE-B68A-9770F970ACBDQ36978998-C83051EF-E5EF-47D2-8931-FC78AA755D13Q37209483-B1A2B308-B2FE-4B88-923C-EFDEE8BE618DQ37308720-B54231A3-FE4D-4719-A98C-6C7393C13CFEQ37643731-B6E2F148-2454-419C-9707-27CE54F2568EQ37643733-E88695FC-E00B-44F2-A5B3-E313D91A619FQ38725610-2EBB2A5B-356B-4736-9C54-D53E6555E25FQ40235609-D48ED4AC-09B6-4989-8D28-5B59CFFE8525Q40339467-7A1CD7A8-D818-45B7-B52D-E5F2DF68DF4BQ40919787-4B8B77BB-5284-474D-A54C-F0062D27B672Q47252143-F5D692D0-88F9-4613-A6ED-752EC0B58405Q47375908-7F897497-AF0E-4677-A74D-D9298ACF862CQ50533334-F065D4CC-B5CA-4938-9EF0-A13DBB520163Q56987707-D4130F85-56C2-452F-A3C7-0204798864E0Q57009763-7E964F0E-3CEE-4740-9316-A7C106065864
P2860
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Insertion of vaccinia virus C7 ...... sponses against HIV-1 antigens
@ast
Insertion of vaccinia virus C7 ...... sponses against HIV-1 antigens
@en
type
label
Insertion of vaccinia virus C7 ...... sponses against HIV-1 antigens
@ast
Insertion of vaccinia virus C7 ...... sponses against HIV-1 antigens
@en
prefLabel
Insertion of vaccinia virus C7 ...... sponses against HIV-1 antigens
@ast
Insertion of vaccinia virus C7 ...... sponses against HIV-1 antigens
@en
P2093
P2860
P1433
P1476
Insertion of vaccinia virus C7 ...... sponses against HIV-1 antigens
@en
P2093
Carlos Oscar Sorzano
José Luis Nájera
Juan García-Arriaza
Mariano Esteban
P2860
P304
P356
10.1371/JOURNAL.PONE.0011406
P407
P577
2010-06-30T00:00:00Z